Seeking Alpha

Aeterna Zentaris (AEZS) +24% after final Phase 3 results for its AEZS-130 drug show that it's...

Aeterna Zentaris (AEZS) +24% after final Phase 3 results for its AEZS-130 drug show that it's safe and effective in diagnosing adult growth hormone deficiency, which can cause diminished lean body mass, poor bone density, and psychological symptoms. (PR)
From other sites
Comments (1)
  • leekell
    , contributor
    Comments (15) | Send Message
     
    WELL GANG ITS BEEN A LONG HAUL..i HUNG IN AND MAYBE WE SEE SOME CONTINUED UPWARD MOVEMENT..HANG IN FOLKS
    26 Jun 2012, 03:49 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs